SYNERTECHCARE

Pioneer in improving cancer treatment

COMPANY BACKGROUND

- Led by Associate Professor Cheng Yuen Yee - University of Technology Sydney
- Key Achievement:
  - Discovered an active ingredient from rice.
  - Otherwise UNAVAILABLE through direct ingestion,
  - Patent filed
- Key Finding:
  - *in vitro* and *in vivo* tests show potential in improving the recovery of damaged cells and tissue of digestive organ

SYNERTECHCARE TEAM

- CEO – Mr Gregory Cheng
  - Founder and CEO of SynerTech International Limited
  - successfully developed many innovative products since 1997. SynerTech products has been sold to EU, US and Japan.
- CSO – A/Prof Yuen Yee Cheng
  - 20 years in oncology studies, two clinical trials, and inventor of Bionis.
  - Current team, Four post-doctoral fellows, one research assistant, seven PhD, two masters, and one honors students.
- Two biomedical and pharmaceutical researchers (in plan)
- Chef Financial Director(in plan) – Experienced in SPAC of USA and chapter 18 of HKEX

ADVISORY BOARD

Prof. Wai Keung Leung (HKU)

- Professor, Medicine, HKU
- Gastroenterology and cancer research expert
- Chief Director, Clinical Trial Center, HKU
- Advice on clinical trial for the company

Dr. Kin Chung Fong Scientist

- Scientist in Raytheon BBN Technology
- Associate of Physics Department at Harvard University.

Prof. David Parker (HKBU)

- Global STEM Chair Professor at HKBU
- Chemist, Royal Collage of Chemistry
- Expert in chemical structures, coordination complexes and conjugates
- Advice on identifying the Active Pharmaceutical Ingredient (API)

Mr Eric S.S. Wong- Chief Consultant

- Founder and president of
  - Hong Kong Jiangsu Exchange Promotion Association (www.hkjs.hk)
  - Hong Kong Huaxia Business Association (www.hkhxba.org)

COMPANY VISION

Our Vision

- Enhance the effectiveness of cancer treatments
- Provide a food-grade additives to improve cancer treatment side effects

Our Mission

- Develop Bionis as an oncology adjuvant to improve the quality of life for cancer patients

CURRENT CHALLENGES IN CANCER TREATMENTS

- **Toxicity and Side Effects,** ***the challenges that Bionis applicable for enhancing Quality of Life***
  - Many cancer treatments harm both cancerous and healthy cells, leading to side effects such as fatigue, nausea, neuropathy, immune suppression, and organ damage.
  - **Between 30% and 85% of cancer patients experience some form of malnutrition during their treatment (Clinical Nutrition Open Science 2023).**

- Resistance
  - Tumours can adapt and become resistant to therapies over time, particularly with chemotherapy and targeted treatments, reducing long-term effectiveness.
- Lack of Precision
  - Some treatments are still not sufficiently personalized or targeted, resulting in generalized approaches that may not suit individual patients' tumour biology.
- Cancer Recurrence
  - Even after successful initial treatment, many patients face recurrence due to minimal residual disease or therapy-resistant cancer cell populations.

PAIN POINT IN GI CANCER TREATMENT

- **Severe Nutritional and Digestive Challenges**
  - Gastrointestinal (GI) cancers often lead to malnutrition due to tumor location and treatment side effects. Tumors can block or impair digestion, while treatments like surgery, chemotherapy, and radiation can cause nausea, vomiting, diarrhea, loss of appetite, and nutrient malabsorption, making it difficult to maintain adequate nutrition.
- **Treatment Complications and Reduced Quality of Life**
  - Nutritional decline and physical weakness negatively impact the ability to tolerate treatment, increasing the risk of complications, delays, and poor outcomes. Combined with fatigue, emotional stress, and changes in eating habits, patients often experience a significantly reduced quality of life.
- **Advantages of Bionis:**
  - Completed proof-of-concept experiments
  - Elucidates the mechanism of action (MOA) as an oncology adjuvant therapy

CORE TECHNOLOGY: BIONIS

- Uses natural plant extracts for medical applications
- Formulated as food-grade additives
- Designed for oral consumption to achieve therapeutic effects
- Prepared as nutritional supplements
- Not synthetic byproducts.
- Easier access with oral form.
- No requirement for hospital administration
- Proven non-toxic, food-grade additives

PROOF OF CONCEPT, DATA – THERAPEUTIC

- Bionis was tested in animals treated with an anticancer drug that induces stomach lining damage.
- Bionis repaired the damaged stomach lining in these animals.
- Provides animals with enhanced general health through Bionis.







BIONIS facilitated chemotherapy and immunotherapy treatment by enhancing treatment efficient in animals



N=5 in each group.

LUNG PATHOLOGY: Bionis Group Shows Less Inflammation



Control



Cisplatin



Anti-PD-1



Cisplatin + Bionis



Anti-PD-1 + Bionis

LIVER PATHOLOGY – Bionis group showed less liver toxicity as compared to chemotherapy



Control



Cisplatin



Anti-PD-1



Cisplatin + Bionis



Anti-PD-1 + Bionis

Tumors in mice treated with Bionis showed higher levels of necrosis and survived longer in trials with chemotherapy and immunotherapy.



Control



Cisplatin



Anti-PD-1



Cisplatin + Bionis



Anti-PD-1 + Bionis

GASTRIC PATHOLOGY – Animals treated with Bionis showed improved gastric health



Control



Cisplatin



Anti-PD-1



Cisplatin + Bionis



Anti-PD-1 + Bionis

BIONIS facilitate anti-cancer treatment via repairing gastric lining and restore nutrition ?



Anti-cancer treated mouse stomach



Mouse stomach after treating with Bionis

BIONIS PATENT APPLICATIONS (2024.10)

Licensed to SynertechCare

- **Australia (2024227788, P1233588.AU) and China (202411526362.4)**
- Methodology to isolate active ingredients and their formulation
- Adjuvant therapy to facilitate cancer treatments.
- Repairs the gastric lining.

Australian Government
IP Australia

30 October 2024

Notice of filing for standard patent application

Griffith Hack
Level 15
376-390 Collins St
MELBOURNE VIC 3000
Australia

Delivering a world leading IP system
Phone: 1300 651 010
International: +61 2 6283 2999
ABN: 38 113 072 755

Your reference: P123358.AU
Application number: 2024227748
Applicant name: Yuen-Yee Cheng

Dear Griffith Hack,

Thank you for filing a standard patent application with IP Australia. This standard patent application has a filing date of 30 October 2024.

Please review the details on the attached application summary to ensure they are correct.

Details of this patent application can be viewed on Australian Patent Search.

Yours sincerely,
IP Australia

Page 1 of 2

国家知识产权局

200333
上海市普陀区云岭西路 600 弄 6 号 7 楼 7028 室 上海光华专利事务所（普通合伙）
许亦琳(021-51096606-829) 余明伟(021-51096606)

发文日：
2025 年 01 月 08 日

号或专利号：202411526362.4　　发文序号：2025010301213700

人或专利权人：郑婉仪

创造名称：枳属/山茶属植物的生物活性提取物的提取方法及应用

发明专利申请初步审查合格通知书

述专利申请，经初步审查，符合专利法实施细则第 50 条的规定。
据专利法第 34 条的规定，专利申请自申请日起满十八个月即行公布。
步审查合格的上述发明专利申请是以：
24 年 10 月 30 日提交的说明书摘要
24 年 10 月 30 日提交的权利要求书
24 年 10 月 30 日提交的说明书
24 年 12 月 25 日提交的说明书附图
基础的。

明专利申请人可以自申请日起 3 年内提交实质审查请求书，缴纳实质审查费，申请人期满未提交实质审查请求书或者缴纳或未缴足实质审查费的，该申请被视为撤回。
利费用可以通过网上缴费、银行/邮局汇款、直接向代办处或国家知识产权局专利局缴纳。缴费时应当写明正确的申请号、费用名称及分项金额。未按供上述信息的视为未办理缴费手续。了解缴费更多详细信息及办理缴费业务，请登录国家知识产权局官方网站。

审查员：高惠
联系电话：010-62089338

国家知识产权局 专利审查业务章

纸件申请，回函请寄：100088 北京市海淀区蓟门桥西土城路 6 号　国家知识产权局专利局受理处收
电子申请，应当通过专利业务办理系统以电子文件形式提交相关文件。除另有规定外，以纸件等其他形式提交的文件视为未提交。

IP PROTECTION AND PROFITABILITY

- Our first patent secures 15 years of market exclusivity — a strong foundation for long-term value.
- We anticipate generating new IP within the next 5–10 years, during which we plan to complete Clinical Phases 1, 2, and 3.
- We project initial revenues starting as early as years 2–3, driven by the first IP-product registration with IFAS, Macau
- With new IP filings along the way, we plan to extend protection and sustain exclusivity well beyond the initial term.
- This strategy positions us to generate substantial returns and maximize the value of this investment.

REGULATORY COMPLIANCE AND MARKET ROAD MAP

We aim to register with the NMPA China before registering with other countries. From project take off

- Step 1, register IFAS Macau 18 months, sells to Great Bay Area China and Portuguese speaking countries
- Step2, Register Blue Cape, another 24 months, sell to whole China
- Step 3, NMPA, another 60 months, Sell to whole China will full listing, and expand to One Belt One Road Countries

When funding allows will complete Phase 1, 2, and 3 clinical trials for US FDA, successful registration will lead to global market access

REGULATORY AND MARKET ESTIMATES

Rank	Country	Estimated New Cases of all cancer(2022)	Regulatory Authority (FDA Equivalent)	Typical Approval Timeframe
1	China	4,571,000	**NMPA** – National Medical Products Administration	12–24 months
2	USA	1,898,160	**FDA** – Food and Drug Administration	6–12 months (priority: ~6 mo)
5	Germany	492,000	EMA / BfArM – European Medicines Agency	12–18 months (EU-wide approval)
6	France	382,000	EMA / ANSM – Nat'l Agency for Medicines	12–18 months (EU process)
7	Italy	377,000	EMA / AIFA – Italian Medicines Agency	12–18 months
8	Japan	374,000	PMDA – Pharmaceuticals and Medical Devices Agency	9–18 months
9	UK	367,000	MHRA – Medicines and Healthcare Products Reg.	6–12 months (post-Brexit route)
13	South Korea	325,000	MFDS – Ministry of Food and Drug Safety	9–15 months
14	Spain	324,000	EMA / AEMPS – Spanish Agency for Med. Prod.	12–18 months
17	Canada	310,000	Health Canada – Health Products & Food Branch	12–18 months (priority: ~6 mo)
18	Australia	309,000	**TGA** – Therapeutic Goods Administration	9–15 months (priority: ~6 mo)

MANUFACTURING, SCABAILITY, OEM AND FOCUS ON R&D

- SynerTechCare focuses on research and development of innovative medical products.

OEM Manufacturing and Scalability:

- Adopt OEM and licensing as production strategy, ensuring complete scalability. Adopts OEM and licensing as a production strategy to ensure full scalability.

Bionis's Own Brand

- Before finalizing agreements with licensing partners, we will market small batches produced by a GMP-certified manufacturer under our own brand. If market response is positive, we plan to scale up production through OEM partners.

COLLABORATION AND LICENSING

- Collaborate with an Australian GMP-certified pharmaceutical company to produce initial batches of medicine for clinical trials.
- Bionis licensees, in exchange for production and sales rights in their country, will contribute resources to register Bionis as a medicine in their respective countries.

LICENSING MODEL

- SynerTechcare will initially lead channel marketing efforts in the Macau, China, Hong Kong, Australia and USA.
- Licensing to major pharma's which have interest in GI cancers treatment
  - Roche, Celgene, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, AstraZeneca, and Merck & Co.
  - Harness their established sales networks in oncology specialists
- Licensing to OEM entities : Co-branding, Production process and technical know-how

INTEREST FROM POTENTIAL CUSTOMERS AND COLLABORATION

- In discussions with Hon-E Haven, a company that sells natural ingredients to cancer patients.
- Sister Company of Hon-E Haven, own and operate GMP facility in Sydney. We will make a few test runs of our production in their facility. This will speed up our development on manufacturing and production processes and hence time to market.

- After the Phase 1 clinical trial, we will accelerate contact with potential partners.

POTENTIAL RISKS AND MITIGATION STRATEGIES

- Active Ingredient Identification May Take Time
  - → Partnered with Prof. David Parker (HKBU), expert in chemical characterization, to guide compound isolation.
- Unpredictable Regulatory Timeline
  - → Early engagement with FDA and consultants to clarify IND/CTA processes and fast-track documentation.
- High Clinical Trial Costs
  - → Engaged Prof. WK Leung (HKU) to lead trials via HKU Clinical Trials Centre, ensuring quality and cost-efficiency.
- Global Investment Slowdown in Biotech
  - → Proactively engaging with investors; early discussions have yielded positive interest.

BIO SAFETY AND BIOETHICS

- We are committed to assembling a research team with deep expertise in laboratory biosafety and translational medicine.
- Leading our regulatory oversight, A/Prof Cheng — a board member of the Human and Medical Ethics Committees at UTS and Sydney Local Health District — She will ensure every Investigational New Drug (IND) and Clinical Trial Authorization (CTA) application adheres strictly to Hong Kong's bioethics standards.
- With this robust governance framework, we're positioned to advance safely, ethically, and with full regulatory confidence.

ACADEMIC PUBLICATIONS

1. **Publications:**

November 2025, first original research article published on Frontier of Pharmacology : Fermented Rice Bran extract delays Skin aging by increasing the Synthesis of collagen and elastin
(https://doi.org/10.3389/fphar.2025.1692491)

Year 1 and 2: Further Publish research on Bionis in scientific journals

1. Investigation of beneficial of Bionis on gastric lining protection

2. The benefit of Bionis to current chemotherapy

3. The nutrition benefit of Bionis

4. The Benefit of Bionis on immunotherapy

FURTHER TESTING

- Acute toxicity
- Repeat-dose toxicity in animals
- Reproductive and developmental toxicity studies
- Genotoxicity studies
- Carcinogenicity studies

TIME TO MARKET

- For the US FDA, completing Phase 1, 2, and 3 clinical trials typically takes around 10 years before a drug can reach the market.
- A key advantage of Bionis is that, during this development period, it can be commercially supplied to hospitals in China through IFAS, the Blue Cape program, and the NMPA registration route as described above.
- Furthermore, it can be marketed as a food additive that promotes gastric health—providing both a revenue stream and ongoing health benefits while we navigate the regulatory process.

PRODUCTS ROADMAP

Target Market

- Patients receiving oral anti-cancer drugs.
- Conduct further testing before extending the product's application to patients receiving radiotherapy, and eventually to all cancer treatment patients.
- Individuals who would like to control their diet but are concerned that fasting may cause gut damage.

MARKET ROAD MAP

Geographical Area:

- After registering under IFAS, begin with Macau, then expand to the Greater Bay Area, followed by NMPA registration, and eventually expand globally.
- Leverage PRC Central Government policies that allow Macau-registered drugs for urgent clinical use in the Greater Bay Area.
- Register under the Blue Cape program and sell to all provinces in the People's Republic of China (PRC).
- In the PRC, register with the National Medical Products Administration (NMPA).
- In Hong Kong, register with the Pharmacy and Poisons Board after FDA approval.
- In all other countries, register with the relevant authorities and engage local distributors or licensees to manage the registration process.

COMPARISON TO COMPETING PRODUCTS

Adjuvant therapies include chemotherapy, radiation therapy, hormone therapy, targeted therapy, and biological therapy.

Oral Adjuvant Products:

Chemotherapy: Oral fluoropyrimidines, such as S-1 (tegafur, gimeracil, and oteracil), are used as adjuvant therapy for gastric cancer and biliary tract cancer.

Hormonal Therapies: For example, abemaciclib in combination with endocrine therapy for early breast cancer.

Targeted Therapies: Afatinib for EGFR mutation–positive non-small cell lung cancer, and neratinib for early-stage hormone receptor–positive, HER2-overexpressed/amplified breast cancer.

After extensive research, we have not identified any products that are similar to or directly comparable with our product.

OUR UNIQUE PRODUCTS

- Oncology Adjuvant
- Repairs Digestive Tract
- Pending FDA, TGA, and NMPA approvals
- No Artificial Additives
- Vegan & Gluten-Free
- Made in a GMP-certified lab in Australia
- Non-Toxic
- Non-Allergic
- Non-Sensitive

PRICING

- **Cost of Adjuvant Oncology Treatment:**
  - Current market range: $118,000 to $440,000 USD per patient.
  - Target cost: $10,000 USD per patient to ensure affordability.
- **Balancing Objectives:**
  - Maintain a balance between providing returns to investors and ensuring affordability for patients.
- **License Fee:**
  - Set at 1.5% of the retail sales price.

PROMOTION STRATEGY

- Collaborate closely with oncology specialists in Hong Kong.
- If sufficient funds are raised, provide free trial sample of the medicine for the first 10,000 patients.
- Based on $10,000 per patient, this represents a sales value of $100 million USD.

TRADE FAIR AND FORUM

- Participate annually in CPHI Worldwide, JP Morgan Healthcare Conference, and Bio International Convention.
- Engage with potential investors, licensees and OEM Partners for our products at these events.


Established extraction material
2016
Established formula
2018
Established animal test
2020
HKPC patent award
2022
Further testing for patent filing
2023
Patent filing lodged
2024
PCT filing lodged
2025
2026
2027
2028
2029
Develop a Bionis-derived API with enhanced anti-cancer properties.
Conduct in vitro and in vivo testing of the new API.
Generate new intellectual property (IP).
Safely test the API in a mouse model.
Use mouse models to confirm Bionis's function.
Small scale of human trial to test safety
Develop a manufacturing process for GMP-compliant production.
Pursue regulatory affairs for FDA approval (6-12 months).